Effects of Continuing or Stopping Alendronate After 5 Years of Treatment
Top Cited Papers
Open Access
- 27 December 2006
- journal article
- research article
- Published by American Medical Association (AMA) in Jama-Journal Of The American Medical Association
- Vol. 296 (24), 2927-2938
- https://doi.org/10.1001/jama.296.24.2927
Abstract
Osteoporosis is common among postmenopausal women, and the disease process is characterized by increased bone turnover, progressive loss of bone mass, microarchitectural deterioration, and increased fracture risk. Bisphosphonates, which are antiresorptive drugs, are the most commonly used pharmacologic treatments for postmenopausal osteoporosis. Alendronate, a potent bisphosphonate, decreases bone turnover, increases bone mineral density (BMD), and decreases vertebral, nonspine, and hip fracture risk in women with osteoporosis.1-4This publication has 34 references indexed in Scilit:
- Seven Years of Treatment with Risedronate in Women with Postmenopausal OsteoporosisCalcified Tissue International, 2004
- Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal womenOsteoporosis International, 2004
- Randomized Trial of Effect of Alendronate Continuation Versus Discontinuation in Women With Low BMD: Results From the Fracture Intervention Trial Long-Term ExtensionJournal of Bone and Mineral Research, 2004
- Bone safety of long-term bisphosphonate treatmentCurrent Medical Research and Opinion, 2004
- Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal WomenThe New England Journal of Medicine, 2004
- Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral FracturesResults From the Fracture Intervention TrialJama-Journal Of The American Medical Association, 1998
- Updated Data on Proximal Femur Bone Mineral Levels of US AdultsOsteoporosis International, 1998
- Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesThe Lancet, 1996
- Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal OsteoporosisThe New England Journal of Medicine, 1995
- Design of the Fracture Intervention TrialOsteoporosis International, 1993